MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos MCO-0-0-02165 10.3892/mco.2020.2165 Articles Impact of postoperative reduced skeletal muscle on prognosis after recurrence in gastric cancer KouzuKeita TsujimotoHironori SugasawaHidekazu IshibashiYusuke ItazakiYujiro TsuchiyaSatoshi KishiYoji UenoHideki Department of Surgery, National Defense Medical College, Tokorozawa, Saitama 359-0042, Japan Correspondence to: Professor Hironori Tsujimoto, Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-0042, Japan tsujihi@ndmc.ac.jp 01 2021 30 10 2020 14 1 3 11 03 2020 21 08 2020 Copyright: © Kouzu et al. 2020 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Little is known about the association between sarcopenia development after gastrectomy and gastric cancer prognosis after recurrence. The present study retrospectively examined the effects of decreased psoas muscle index (PMI) on post-recurrence prognosis after gastrectomy. A total of 67 patients with gastric cancer recurrence were included in the present study. PMI at pre-operation and recurrence were calculated, and 25 patients whose PMI reduction rate value was lower than the cutoff values (male=0.766 and female=0.704) were classified into the sarcopenia group and 42 patients into the non-sarcopenia group. There were no significant differences between the groups regarding age, sex, pathological stage, and nutrition and inflammation indices at the time of recurrence. Post-recurrence overall survival (OS) was significantly shorter in the sarcopenia group compared with the non-sarcopenia group (P<0.001). The post-recurrence survival rate was significantly worse in the sarcopenia group compared with the non-sarcopenia group (P<0.001). In multivariate analysis, sarcopenia (HR=5.04) and the total courses of chemotherapy after recurrence (HR=3.88) were independent unfavorable prognostic factors. In conclusion, sarcopenia and fewer total courses of post-recurrence chemotherapy were poor prognostic factors after gastric cancer recurrence. To improve prognosis, preventing sarcopenia development after gastrectomy is required.

 gastric cancer chemotherapy sarcopenia prognosis Introduction

Despite ongoing advances in diagnostics, operative technique, and treatment strategy for the decades, gastric cancer remains one of the most common cancers in the world and a lethal disease (1). Gastrectomy for gastric cancer is essential for improving the survival rate, it may cause persistent functional disorders such as reduced amount of oral intake, insulin resistance, increased protein catabolism, and metabolic changes, leading to weight loss and the development of sarcopenia (2). It is reported that preoperative sarcopenia has been associated with long-term prognosis as well as short-term outcomes such as the development of postoperative pneumonia, poor activities of daily living, longer hospital stay, and the incidence of postoperative complications (3-10), which may restrict the following treatment options (11). Treatment option for patient with recurrence of gastric cancer after gastrectomy is limited to chemotherapy or best supportive care. It is known that sarcopenia could influence on pharmacokinetics of chemotherapy which could be associated with adverse effects of chemotherapy in several cancers (4). However, little is known about the effects of reduced skeletal muscle volume after gastrectomy on prognosis and treatment strategy after the recurrence of gastric cancer. In the present study, we investigated the effects of reduced skeletal muscle volume after gastrectomy on the treatment and prognosis in patients with recurrent gastric cancer.

 Materials and methods <sec> <title>Patients

The study protocol was approved by the Institutional Review Board of National Defense Medical College (Saitama, Japan). Of the 553 patients who underwent radical gastrectomy for gastric cancer at the National Defense Medical College between 2011 and 2016, 67 patients who had gastric cancer recurrence were included in this study. We retrospectively evaluated the clinicopathological findings, serum albumin levels, C-reactive protein (CRP), total cholesterol, and neutrophil and lymphocyte counts at the time of preoperative and recurrence of gastric cancer. In addition, the neutrophil-lymphocyte ratio (NLR), the CRP-albumin ratio (CAR), the controlling nutrition status (CONUT) score, the prognostic nutritional index (PNI), and the modified Glasgow prognostic (mGPS) score were calculated as markers of nutrition or inflammation.

The tumor pathological findings were recorded in accordance with the third English edition of the Japanese Classification of Gastric Carcinoma, edited by the Japanese Gastric Cancer Association (12). All patients were followed-up using an oncologically appropriate plan on a per-patient basis. For patients with stage II or III disease, postoperative adjuvant chemotherapy with S-1 (80 mg/m²/day) was recommended for 1 year. In 45 cases of pathological stage II or III gastric cancer patients, 26 cases (57.8%) received adjuvant chemotherapy. There was no significant correlation between age and receiving adjuvant chemotherapy.

 Definition of sarcopenia

The psoas muscle index (PMI: cm2/m2) was calculated from CT images (Aquilion 64; Toshiba Medical Systems) and the psoas muscle cross-sectional area at the third lumbar vertebra (L3) normalized length preoperatively and at the recurrence of gastric cancer by a physician who was blinded to the clinicopathological characteristics of the patients (Fig. 1) (13,14). The reduction rate of PMI from the preoperative value to that at the recurrence of gastric cancer was calculated. The patients were divided into two groups by the cutoff value using area under the receiver operating characteristic curves (ROC); the sarcopenia group (n=25 patients) had less than the cutoff value of the reduction rate of PMI (male=0.766 and female=0.704), and the non-sarcopenia group (n=42 patients) had more than the cutoff value (Fig. 2). The median value of the total cohort was 0.793.

 Statistical analyses

All statistical analyses were performed using the JMP® Pro 14.0.0 software package (SAS Institute Inc.). The Student's t-test and Pearson's Chi-square test were performed, as appropriate. A receiver operating characteristics (ROC) curve was constructed to estimate the optimal cutoff value of the reduction of PMI. Survival rates were obtained by the Kaplan-Meier method, and the statistical significance was determined by the log-rank test.

Univariate and multivariate analyses were performed using the Cox proportional hazards regression model. The data are expressed as mean ± standard deviation. A P-value of <0.05 was considered statistically significant.

 Results <sec> <title>Patient characteristics

Patients' clinical factors at the recurrence of gastric cancer and pathological factors diagnosed from resected specimens are shown in Table I. There were no significant differences in age, sex, Charlson Comorbidity Index score, and surgical procedure including reconstruction methods between the two groups. The sarcopenia group had a higher body weight and body mass index (BMI) than did the non-sarcopenia group. In addition, the reduction rates of body weight and BMI due to the recurrence of gastric cancer in the sarcopenia group were higher than those of the non-sarcopenia group. There was no significant difference in the pathological factors between the two groups except for tumor depth. The NLR, CAR, CONUT score, PNI, and mGPS at the recurrence of gastric cancer were not significantly different between the two groups (Table II). There was no significant difference in the time between gastrectomy and recurrence, the number of patients who received adjuvant chemotherapy and chemotherapy after the recurrence, the number of discontinued chemotherapies due to adverse effect, the number of chemotherapy regimens after recurrence, the kind of basic chemotherapy after recurrence, and the total courses of chemotherapies between the two groups. The sarcopenia group had a significantly shorter OS from recurrence than did the non-sarcopenia group (median survival time, interquartile range: 118, 43.5-180.5 vs. 300, 133.8-636.3 days, P<0.001).

 Prognostic factors

The survival rate from the time of recurrence in the sarcopenia group was significantly worse than that in the non-sarcopenia group (3-year OS 6.0% vs. 21.0%, P<0.001; Fig. 3). Univariate and multivariate analyses that might affect the survival rate from the time of the recurrence of gastric cancer were shown in Table III. Univariate analysis demonstrated that the total courses of chemotherapy after recurrence <5 [hazard ratio (HR)=3.82], sarcopenia (HR=2.66), NLR ≥3.0 (HR=2.63), and PNI ≤40 (HR=2.59) were significantly associated with the prognosis after recurrence. The sarcopenia group more frequently had peritoneal recurrence, which didn't affect prognosis.

Multivariate analysis revealed that sarcopenia at the recurrence (HR=5.04) and the total courses of chemotherapy after recurrence (HR=3.88) were independent unfavorable prognostic factors.

Table IV shows univariate and multivariate analysis for the OS from the time at recurrence among the difference time of sarcopenia. Sarcopenia at the recurrence and the reduction rate of PMI from surgery to the recurrence were selected as the independent poor prognostic factors via multivariate analysis, but preoperative sarcopenia was not.

 Discussion

In the present study, we demonstrated that the high reduction rate of PMI from the preoperative value to that at the recurrence of gastric cancer and the fewer courses of chemotherapy performed after recurrence were independently associated with poor prognosis after the recurrence.

Since Rosenberg has reported the concept of sarcopenia in 1997, and many studies have evaluated the associations between sarcopenia and clinical factors, such as poor quality of life, aspiration pneumonia, osteoporosis, swallowing function, and respiratory function (15). In patients with malignancies, sarcopenia is more likely to be developed due to increased protein catabolism, inflammatory reactions, metabolic abnormalities, and poor oral intake and may be associated with cancer cachexia. Many recent studies have shown that the frequency of serious postoperative complications was high and the long-term prognosis was poor in gastric cancer patients with preoperative sarcopenia (5-7,9,10). In addition, postoperative loss of the muscle mass affects the continuation rate of postoperative adjuvant chemotherapy, especially in the elderly, because of increased severe adverse events (16,17). However, no study has evaluated the relationship between prognosis after the recurrence and the reduction of skeletal muscle mass after gastrectomy. This study indicated that the reduction of PMI was a risk factor of poor OS after the recurrence of gastric cancer, which is consistent with a previous report that skeletal muscle loss during postoperative adjuvant chemotherapy is associated with poor prognosis (18).

We also demonstrated that patients who failed to continue chemotherapy more than five courses after the recurrence of gastric cancer had a poor prognosis. There are several factors affecting the continuity of chemotherapy after the recurrence, i.e., adverse events, age, performance status, the amounts of oral intakes, economic problem, and other social circumstances (19). Physicians can intervene the continuity of chemotherapy by providing appropriate nutritional management and preventing loss of skeletal muscle mass at the time of recurrence, which may be associated with longer survival after the recurrence of gastric cancer.

Preoperative exercises and nutritional support programs were effective for increasing total caloric intake, protein, and grip strength, maintaining skeletal muscle volume and improving postoperative outcomes in patients with gastric cancer (19,20). However, there were few reports on the effects of postoperative nutritional supports on the postoperative development of sarcopenia and outcome. In addition, it has been reported that subtotal gastrectomy for the upper third of gastric cancer had advantages over total gastrectomy in terms of maintaining weight and nutritional status (20,21). Thus, it will be essential to ensure thorough nutritional management after surgery, as well as surgical procedures, for maintaining skeletal muscle volume and nutritional status at the recurrence of gastric cancer.

In the present study, we also evaluated the NLR, CAR, PNI, CONUT, and mGPS at the recurrence of gastric cancer, which were well known to be preoperative prognostic markers in various malignancies (22-26). We demonstrated that these markers were not associated with prognosis when the values at the recurrence were used, indicating the importance of preoperative value but not at the recurrence.

We compared the clinical importance of the sarcopenia preoperatively, at the recurrence, and the reduction rate of PMI from surgery to the recurrence. Sarcopenia at the recurrence and the reduction rate of PMI from surgery to the recurrence were selected as the independent poor prognostic factors by multivariate analysis.

This study has several potential limitations. The retrospective design of the study and relatively small number of patients in this study may have resulted in bias. In addition, we did not evaluate the relation of amounts of oral intake and the exercise after gastrectomy to the occurrence of gastric cancer, which made it difficult to determine whether skeletal muscle loss was caused by eating disorder after gastrectomy or with the progression of cancer.

In conclusion, fewer total courses of chemotherapy after recurrence and sarcopenia were poor prognostic factors for patients with gastric cancer recurrence. Our data suggested that prospective interventional study to prevent the reduction of skeletal muscle volume should be promising for improving survival after the recurrence of gastric cancer.

 Acknowledgements

Not applicable.

 Funding

No funding was received.

 Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

 Authors contributions

KK, HT, HS, YIt, YIs, ST, YK and HU contributed to the study conception and design. Material preparation and data collection and analysis were performed by KK. The first draft of the manuscript was written by KK and HT, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

All procedures followed were in accordance with the Helsinki Declaration of 1964 and later versions. The study protocol was approved by the Institutional Review Board of the National Defense Medical College, and written informed consent was obtained from every patient.

 Patient consent for publication

Informed consent for publication was obtained from every patient.

 Competing interests

The authors declare that they have no competing interests.

 References SiegelRLMillerKDJemalACancer statistics, 2020CA Cancer J Clin7073020203191290210.3322/caac.21590 Cruz-JentoftAJBaeyensJPBauerJMBoirieYCederholmTLandiFMartinFCMichelJPRollandYSchneiderSMSarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older peopleAge Ageing3941242320102039270310.1093/ageing/afq034 NagataKTsujimotoHNagataHHaradaMItoNKanematsuKNomuraSHoriguchiHHirakiSHaseKImpact of reduced skeletal muscle volume on clinical outcome after esophagectomy for esophageal cancer: A retrospective studyMedicine (Baltimore)97e1145020183004526810.1097/MD.0000000000011450 AntounSBorgetILanoyEImpact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancerCurr Opin Support Palliat Care738338920132418989310.1097/SPC.0000000000000011 FukudaYYamamotoKHiraoMNishikawaKNagatsumaYNakayamaTTanikawaSMaedaSUemuraMMiyakeMSarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomyGastric Cancer1998699320162640787510.1007/s10120-015-0546-4 HuangDDChenXXChenXYWangSLShenXChenXLYuZZhuangCLSarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: A prospective studyJ Cancer Res Clin Oncol1422347235620162757338510.1007/s00432-016-2230-4 KawamuraTMakuuchiRTokunagaMTanizawaYBandoEYasuiHAoyamaTInanoTTerashimaMLong-term outcomes of gastric cancer patients with preoperative sarcopeniaAnn Surg Oncol251625163220182963309510.1245/s10434-018-6452-3 OngaroEBuoroVCinauseroMCaccialanzaRTurriAFanottoVBasileDVitaleMGErmacoraPCardellinoGGSarcopenia in gastric cancer: When the loss costs too muchGastric Cancer2056357220172847710610.1007/s10120-017-0722-9 WangSLZhuangCLHuangDDPangWYLouNChenFFZhouCJShenXYuZSarcopenia adversely impacts postoperative clinical outcomes following gastrectomy in patients with gastric cancer: A prospective studyAnn Surg Oncol2355656420162666808510.1245/s10434-015-4887-3 ZhuangCLHuangDDPangWYZhouCJWangSLLouNMaLLYuZShenXSarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: Analysis from a large-scale cohortMedicine (Baltimore)95e316420162704367710.1097/MD.0000000000003164 GosneyMAClinical assessment of elderly people with cancerLancet Oncol679079720051619898510.1016/S1470-2045(05)70389-2 Japanese Gastric Cancer AssociationJapanese classification of gastric carcinoma: 3rd English editionGastric Cancer1410111220112157374310.1007/s10120-011-0041-5 HamaguchiYKaidoTOkumuraSKobayashiAHammadATamaiYInagakiNUemotoSProposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adultsNutrition321200120520162729277310.1016/j.nut.2016.04.003 MourtzakisMPradoCMLieffersJRReimanTMcCargarLJBaracosVEA practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careAppl Physiol Nutr Metab33997100620081892357610.1139/H08-075 RosenbergIHSarcopenia: Origins and clinical relevanceJ Nutr127 (5 Suppl)990S991S1997916428010.1093/jn/127.5.990S AoyamaTKawabeTFujikawaHHayashiTYamadaTTsuchidaKYukawaNOshimaTRinoYMasudaMLoss of lean body mass as an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancerAnn Surg Oncol222560256620152551519910.1245/s10434-014-4296-z ShenYHaoQZhouJDongBThe impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: A systematic review and meta-analysisBMC Geriatr1718820172882640610.1186/s12877-017-0569-2 SugiyamaKNaritaYMitaniSHondaKMasuishiTTaniguchiHKadowakiSUraTAndoMTajikaMMuroKBaseline sarcopenia and skeletal muscle loss during chemotherapy affect survival outcomes in metastatic gastric cancerAnticancer Res385859586620183027521110.21873/anticanres.12928 Japanese Gastric Cancer AssociationJapanese gastric cancer treatment guidelines 2014 (ver. 4)Gastric Cancer2011920172734268910.1007/s10120-016-0622-4 YamamotoKNagatsumaYFukudaYHiraoMNishikawaKMiyamotoAIkedaMNakamoriSSekimotoMFujitaniKTsujinakaTEffectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancerGastric Cancer2091391820172803223210.1007/s10120-016-0683-4 KosugaTHikiNNunobeSNomaHHondaMTanimuraSSanoTYamaguchiTFeasibility and nutritional impact of laparoscopy-assisted subtotal gastrectomy for early gastric cancer in the upper stomachAnn Surg Oncol212028203520142455806210.1245/s10434-014-3520-1 IshibashiYTsujimotoHHirakiSKumanoIYaguchiYHoriguchiHNomuraSItoNShintoEAosasaSPrognostic value of preoperative systemic immunoinflammatory measures in patients with esophageal cancerAnn Surg Oncol253288329920183001930410.1245/s10434-018-6651-y ForrestLMMcMillanDCMcArdleCSAngersonWJDunlopDJEvaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancerBr J Cancer891028103020031296642010.1038/sj.bjc.6601242 IshibashiYTsujimotoHYaguchiYKishiYUenoHPrognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysisAnn Gastroenterol Surg4566320193202195910.1002/ags3.12294 Ignacio de UlíbarriJGonzález-MadroñoAde VillarNGGonzálezPGonzálezBManchaARodríguezFFernándezGCONUT: A tool for controlling nutritional status. First validation in a hospital populationNutr Hosp203845200515762418 ToyokawaTKuboNTamuraTSakuraiKAmanoRTanakaHMugurumaKYashiroMHirakawaKOhiraMThe pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: Results from a retrospective studyBMC Cancer1672220162759946010.1186/s12885-016-2696-0

Sarcopenia was defined as the case with less PMI reduction rate value than the sex-specific cut-off values. The psoas muscle mass was measured using a manually traced area as presented by the dotted line. (a) non-sarcopenia case and (b) sarcopenia case. PMI, psoas muscle index.

Changes in PMI from preoperative to recurrence in all patients; the sarcopenia group exhibited <cutoff value of the reduction rate of PMI (male=0.804 and female=0.733), and the non-sarcopenia group exhibited >the cutoff value. Open circles represent male cases and filled circles represent female cases. PMI, psoas muscle index.

The overall survival from the time of recurrence. Log-rank test, P<0.05.

Patient's clinicopathological factors.

Characteristic Sarcopenia (n=25, 37.3%) Non-Sarcopenia (n=42, 62.7%) Total (n=67) P-value
Age 72.1±7.8 70.0±8.6 70.8±8.3 0.393
Sex       0.718
     Male 20 32 52  
     Female 5 10 15  
Body weight (kg)        
     Preoperatively 55.4±8.9 59.5±9.8 57.9±9.6 0.082
     At the time of recurrence 46.2±8.1 51.2±7.9 49.3±8.3 0.014a
     Recurrence/preoperatively 0.8±0.1 0.9±0.1 0.9±0.1 0.422b
Body mass index (kg/m2)        
     Preoperatively 21.3±2.9 22.6±3.2 22.1±3.1 0.071
     At the time of recurrence 17.7±2.2 19.5±2.6 18.8±2.6 0.010a
     Recurrence/preoperatively 0.8±0.1 0.9±0.1 0.9±0.1 0.338
Psoas muscle index        
     Preoperatively 3.9±0.9 3.7±1.1 3.8±1.0 0.223
     At the time of recurrence 2.5±0.8 3.2±1.0 3.0±1.0 0.005a
     Recurrence/Preoperatively 0.6±0.1 0.9±0.1 0.8±0.2 <0.001a
CCI score 2≤       0.630
     Yes 6 8 14  
     No 19 34 53  
Tumor location U/M/L       0.579
     U 11 15 26  
     M 9 12 21  
     L 5 15 20  
Histology int/dif/other       0.210
     Int 14 18 32  
     Dif 8 22 30  
     Other 3 2 5  
Tumor depth       0.418
     pT1 4 (16.0%) 3 (7.1%) 7 (10.5%)  
     pT2 3 (12.0%) 3 (7.1%) 6 (9.0%)  
     pT3 7 (28.0%) 19 (45.2%) 26 (38.8%)  
     pT4 11 (44.0%) 17 (40.5%) 28 (41.8%)  
Lymph node metastasis       0.978
     pN0 5 (20.0%) 8 (19.1%) 13 (19.4%)  
     pN1 4 (16.0%) 8 (19.1%) 12 (17.9%)  
     pN2 6 (24.0%) 11 (26.2%) 17 (25.4%)  
     pN3 10 (40.0%) 15 (35.7%) 25 (37.3%)  
Pathological cancer stage       0.267
     pStageI 3 (12.0%) 3 (7.2%) 6 (9.1%)  
     pStageII 6 (24.0%) 12 (28.6%) 18 (27.3%)  
     pStageIII 16 (64.0%) 27 (64.3%) 43 (63.6%)  
Lymphatic invasion       0.613
     Ly0 2 5 7  
     Ly1 23 37 60  
Venous invasion       0.429
     V0 4 4 8  
     V1 21 38 59  
DG/TG/other       0.161
     DG 6 19 25  
     TG 17 22 39  
     Other 2 1 3  
Open/laparoscopy       0.161
     Open 18 23 41  
     Laparoscopy 7 19 26  
Billroth-I/Roux-en-Y/other       0.130
     Billroth-I 6 15 21  
     Roux-en-Y 2 27 44  
     Other 17 0 2  
Recurrence pattern       0.455
     Peritoneal 9 (36.0%) 9 (7.1%) 18 (26.9%)  
     Hematogenous 6 (24.0%) 17 (7.1%) 23 (34.3%)  
     Lymph node 6 (24.0%) 11 (7.1%) 17 (25.4%)  
     Local 2 (8.0%) 1 (7.1%) 3 (4.5%)  
     Other 2 (8.0%) 4 (45.2%) 6 (8.9%)  

U, upper third; M, middle third; L, lower third; Int, intestinal type; Dif, diffuse type; DG, Distal gastrectomy; TG, Total gastrectomy; CCI, Charlson comorbidity index;

aP<0.05. Data are expressed as the mean ± standard deviation.

Patient's characteristics at the time of recurrence of gastric cancer.

Characteristic Sarcopenia (n=25, 37.3%) Non-Sarcopenia (n=42, 62.7%) Total (n=67) P-value
Neutrophil lymphocyte ratio        
     Preoperatively 3.0±2.4 3.5±2.8 3.3±2.6 0.828
     At the time of recurrence 4.2±3.1 4.6±4.7 4.5±4.1 0.589
CAR        
     Preoperatively 0.3±0.4 0.1±0.2 0.2±0.3 0.213
     At the time of recurrence 0.7±1.0 0.5±0.6 0.6±0.8 0.474
CONUT score        
     Preoperatively 2.3±1.1 2.5±1.3 2.4±1.2 0.597
     At the time of recurrence 4.8±2.8 3.0±1.7 3.9±2.5 0.062
Prognostic nutritional index        
     Preoperatively 37.2±9.5 35.9±13.3 36.4±11.7 0.746
     At the time of recurrence 39.7±7.5 43.7±9.0 42.1±8.6 0.114
Modified GPS score        
     Preoperatively 0.4±0.7 0.5±0.7 0.5±0.7 0.927
     At the time of recurrence 1.2±0.7 1.0±0.6 1.1±0.7 0.180
Adjuvant chemotherapy       0.874
     Yes 8 16 24  
     No 17 26 43  
Discontinued adjuvant chemotherapy due to adverse effect 6 (75.0%) 10 (62.5%) 16 (66.7%) 0.540
Duration from gastrectomy to recurrence (day) 572.9±513.2 444.8±331.0 492.6±409.5 0.484
Chemotherapy after recurrence       0.729
     Yes 12 22 34  
     No 13 20 33  
1st line regimen after recurrence       0.100
     Pyrimidine fluoride 8 20 28  
     Taxane 2 2 4  
     Other 2 0 2  
Number of chemotherapy regimens after recurrence 1.6±0.8 1.7±1.0 1.7±0.9 0.855
Total courses of chemotherapy after recurrence 3.7±2.4 7.5±5.6 6.3±5.1 0.092
Discontinued chemotherapy due to adverse effect 6 (50.0%) 7 (31.8%) 13 (38.2%) 0.297
Overall survival from the recurrence of gastric cancer (day) 169.0±52.8 492.9±83.4 372.0±58.8 <0.001

CAR, C-reactive protein Albumin ratio; CONUT, controlling nutrition status; GPS, Glasgow Prognostic Score. Data are expressed as the mean ± standard deviation.

Prognostic factor for the overall survival from the time at recurrence.

  Univariate analysis Multivariate analysis
Characteristic HR 95% CI P-value HR 95% CI P-value
Age 1.69 0.91-3.22 0.096      
     ≥70 years old            
Body weight reduction rate 1.24 0.67-2.28 0.490      
     ≥Median            
Body mass index reduction rate 1.21 0.65-2.23 0.530      
     ≥Median            
CCI score 0.90 0.37-1.92 0.802      
     ≥2            
Tumor depth 0.71 0.35-1.66 0.404      
     ≥pT3            
Lymph node metastasis 1.65 0.88-3.24 0.117      
     ≥pN2            
Lymphatic invasion 0.99 0.45-2.62 0.984      
     Ly1            
Venous invasion 0.95 0.43-2.52 0.908      
     V1            
Neutro Lymph ratio 2.63 1.28-5.53 0.008a 1.48 0.40-5.01 0.544
     ≥3.0            
CONUT score 2.26 0.90-6.20 0.084      
     ≥4            
Prognostic Nutritional Index 2.59 1.23-5.50 0.012a 1.25 0.33-5.01 0.746
     ≤40            
modified GPS score 1.91 0.90-4.70 0.097      
     ≥1            
Sarcopenia 4.18 2.17-8.07 <0.001a 5.04 1.28-22.61 0.021a
     Yes            
Adjuvant chemotherapy 1.05 0.58-1.93 0.872      
     No            
Recurrence site 1.49 0.75-2.80 0.246      
     Peritoneal            
Chemotherapy after recurrence 1.32 0.71-2.43 0.376      
     No            
Chemotherapy regimen after recurrence 0.45 0.16-1.59 0.192      
     Pyrimidine fluoride            
Number of regimens after recurrence 1.13 0.50-2.58 0.762      
     <2            
Total courses of chemotherapy after recurrence 3.82 1.33-11.42 0.013a 3.88 1.19-13.69 0.025a
     <5            

HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; CONUT, controlling nutrition status; GPS, Glasgow Prognostic Score; CCI, Charlson comorbidity index.

aP<0.05.

Univariate and multivariate analysis for the overall survival from the time at recurrence among the difference time of sarcopenia.

  Univariate analysis Multivariate analysis
    HR 95% CI P-value HR 95% CI P-value
Sarcopenia by skeletal muscle mass reduction rate Yes 4.18 2.17-8.07 <0.001a 3.05 1.44-6.48 0.004a
Preoperative sarcopenia Yes 0.93 0.51-1.73 0.813 0.80 0.39-1.67 0.551
Sarcopenia at the time of recurrence Yes 3.58 1.78-7.42 <0.001a 3.05 1.30-7.31 0.010a

HR, hazard ratio; CI, confidence interval.

aP<0.05.